Adjuvant Capecitabine-Containing Chemotherapy Benefit and Homologous Recombination Deficiency Status Among Early-Stage TNBC Patients in the FinXX trial
Leonora W. de Boo(The Netherlands Cancer Institute), Sabine C. Linn(Oncode Institute), Susanna Lauttia(University of Helsinki), Philip C. Schouten(Cambridge University Hospitals NHS Foundation Trust), Michael Hauptmann(Medizinische Hochschule Brandenburg Theodor Fontane), Henrik Lindman(Uppsala University), Roelof J.C. Kluin(The Netherlands Cancer Institute), Marleen Kok(The Netherlands Cancer Institute), Petra M. Nederlof(The Netherlands Cancer Institute), Charlaine van Steenis(The Netherlands Cancer Institute), Wim Brugman(The Netherlands Cancer Institute), Mark Opdam(The Netherlands Cancer Institute), Heikki Joensuu(Orion Corporation (Finland)), Katarzyna Jóźwiak(The Netherlands Cancer Institute)
Cited by 1
Related Papers
Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal Tumors
|New England Journal of Medicine|2002|4.4k
Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2018|1.6k
Adjuvant Docetaxel or Vinorelbine with or without Trastuzumab for Breast Cancer
|New England Journal of Medicine|2006|1.4k